Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19

NCT05085574 is registered in ClinicalTrials.gov with Leidos Life Sciences as lead sponsor.

NCT NCT05085574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19
Lead sponsor
Leidos Life Sciences
Phase
Phase 2
Overall status
Withdrawn
Start date
February 7, 2023
Completion date
February 7, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

2019 novel coronavirus disease, 2019 novel coronavirus infection, 2019-ncov disease, 2019-ncov infection, coronavirus disease 2019, covid-19, covid-19 pandemic, covid-19 virus disease, covid-19 virus infection, covid19, sars-cov-2 acute respiratory disease, sars-cov-2 infection